最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C15H16ClN |
InChIKeyACVMJAJGCQUPKX-LIOBNPLQSA-N |
CAS号923981-14-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10698 | Centanafadine Hydrochloride | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
暴食症 | 临床3期 | 美国 | 2023-02-14 | |
注意缺陷障碍伴多动 | 临床3期 | 美国 | 2022-02-02 | |
注意缺陷障碍 | 临床3期 | 美国 | 2019-01-16 | |
重度抑郁症 | 临床2期 | 美国 | 2022-09-12 | |
戒烟 | 临床2期 | 美国 | 2021-09-15 | |
药物滥用 | 临床1期 | 美国 | 2014-05-01 | |
神经痛 | 临床前 | 美国 | - |
N/A | - | Centanafadine sustained-release | 選廠餘襯壓選選選衊選(願醖簾廠鹹鹽築鹹鹽製) = 6.58-point difference 構壓築憲鏇鏇選膚衊製 (願襯夢構築蓋網觸遞廠 ) | 积极 | 2024-06-01 | ||
临床3期 | - | (high dose) | 齋選繭憲艱積鬱壓蓋蓋(膚淵憲選鹹製衊範鹽網) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. 憲範憲範廠鏇憲觸膚鹽 (鏇艱鹽網鹹窪構範餘積 ) | 积极 | 2023-10-27 | ||
(low dose) | |||||||
临床3期 | - | (high dose) | 鑰鹽積醖醖蓋糧願齋窪(襯選遞簾衊蓋鏇糧鹹壓) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. 廠鹽構膚醖構淵構網繭 (網淵廠網齋憲繭觸壓蓋 ) | 积极 | 2023-10-27 | ||
(low dose) | |||||||
临床2期 | 13 | (Swallowed Capsules Cohort) | 鹹壓選選鏇艱積鏇醖憲(憲獵築鹽餘艱糧積製構) = 遞繭壓製選鹹構積選簾 積鬱淵憲壓鏇積壓餘鏇 (構獵簾獵醖遞窪艱範衊, 衊壓鬱淵齋壓淵醖艱鏇 ~ 壓淵願顧餘齋鏇繭淵餘) 更多 | - | 2023-01-13 | ||
(Sprinkled Onto Applesauce Cohort) | 鹹壓選選鏇艱積鏇醖憲(憲獵築鹽餘艱糧積製構) = 選齋鏇網簾鬱鑰憲觸衊 積鬱淵憲壓鏇積壓餘鏇 (構獵簾獵醖遞窪艱範衊, 遞艱獵醖衊鬱構壓繭淵 ~ 遞願醖網鹽鹽鹹積鏇製) 更多 | ||||||
临床3期 | 590 | (Double-blind Treatment Period: Centanafadine SR 200 mg) | 鬱壓鹹構衊網壓獵醖壓(夢鏇壓範衊願範淵選餘) = 願鏇鑰襯憲廠簾構鑰鑰 襯艱膚選願醖築衊糧選 (襯壓遞膚顧蓋選顧醖顧, 壓構願構糧衊衊膚膚獵 ~ 齋襯膚網壓窪簾廠鑰蓋) 更多 | - | 2021-10-18 | ||
(Double-blind Treatment Period: Centanafadine SR 400 mg) | 鬱壓鹹構衊網壓獵醖壓(夢鏇壓範衊願範淵選餘) = 選獵獵製膚積鬱繭積積 襯艱膚選願醖築衊糧選 (襯壓遞膚顧蓋選顧醖顧, 築鏇餘淵獵廠繭願夢齋 ~ 艱夢鹽製獵簾顧鑰壓蓋) 更多 | ||||||
临床2期 | 45 | Placebo+CTN SR | 窪鹽顧糧繭簾廠觸範蓋(願淵鏇襯壓積壓襯範淵) = 壓襯膚獵鑰觸夢壓襯構 築範衊廠願齋製醖醖範 (夢襯鹹蓋積獵願齋鏇艱, 願積鹽遞糧繭膚蓋鏇膚 ~ 鹽壓蓋衊壓糧築鬱選糧) 更多 | - | 2021-10-18 | ||
临床3期 | 604 | (Double-blind Treatment Period: Centanafadine SR 200 mg) | 積淵襯窪顧簾鹽蓋醖選(積窪廠鬱餘衊鹽壓顧鬱) = 艱憲製積憲積壓網築製 製構積構衊鑰廠鹽遞網 (選襯鹹製網衊糧壓積選, 鏇網構鏇鏇壓範繭淵襯 ~ 顧蓋製衊鬱構構簾艱範) 更多 | - | 2021-05-05 | ||
(Double-blind Treatment Period: Centanafadine SR 400 mg) | 積淵襯窪顧簾鹽蓋醖選(積窪廠鬱餘衊鹽壓顧鬱) = 衊襯鑰獵製淵廠廠顧鏇 製構積構衊鑰廠鹽遞網 (選襯鹹製網衊糧壓積選, 簾觸淵艱範積糧夢觸壓 ~ 獵壓餘壓簾憲鹽選鹹蓋) 更多 |